Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.

摘要: Paraneoplastic pemphaigus (PNP) is a rare autoimmune mucocutaneous blistering disease that commonly associated with underlying B-cell neoplasms. There no standard therapy for PNP. Potent immunosuppression has been the only potentially effective treatment in setting of malignancy because there correlation between tumor burden and activity disease. Two recent case reports have noted resolution lesions PNP after CD20+ lymphomas rituximab. Rituximab an anti-CD20 antibody had some success treating proliferative disorders. We report lymphoma did not respond to this novel therapy, discuss rituximab's putative mechanism action along clinical settings which may prove useful